Protein Binding of a Novel Platinum-Based Anticancer Agent BP-C1 Containing a Lignin-Derived Polymeric Ligand
Source abstract
Abstract
Platinum (Pt) antineoplastic agents remain indispensable for the treatment of oncological disease. Pt-based drugs are mainly used in the therapy of ovarian cancer and non-small-cell lung carcinoma. A novel platinum-containing antineoplastic agent BP-C1 is a complex of diamminoplatinum with an oxygen-donor polymeric ligand of benzene-polycarboxylic acids, isolated from natural lignin. The aim of the study was to investigate ex vivo protein binding of BP-C1. Protein binding of BP-C1 was tested using equilibrium dialysis. Pooled blood plasma was used in the study. Control solutions contained the same dosages of BP-C1 in PBS (pH 7.2). Plasma and control solutions were submitted to equilibrium dialysis across a vertical 8 kDa cut-off membrane for 4 h at 37 °C under gentle shaking. Platinum was quantified in dialysis and retained fractions using inductively coupled plasma mass spectrometry after microwave digestion. The dialysis system was tested and validated; this showed no protein saturation with platinum. A medium degree of binding of platinum to macromolecular species of ca. 60% was observed. The study showed the maintenance of a high fraction of free BP-C1 in the bloodstream, facilitating its pharmacological activity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Metal complexes synthesis and properties · Chronic Myeloid Leukemia Treatments · Ferrocene Chemistry and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
N.N. Petrov National Medical Research Center of Oncology, 197758 Saint Petersburg, Russia
Nobel Ltd., 192012 Saint Petersburg, Russia
Institute of Toxicology, Federal Medical Biological Agency, 192019 Saint Petersburg, Russia
Institute of Technology Sligo, Ash Lane, F91 YW50 Sligo, Ireland
Funding
Russian Science Foundation
References (38)
Show source-provided references
1. Platinum speciation used for elucidating activation or inhibition of Pt-containing anti-cancer drugs10.1016/j.jtemb.2010.01.006 ↗
2. Platinum compounds—A new class of potent antitumour agents10.1038/222385a0 ↗
3. Platinum drugs in the treatment of non-small-cell lung cancer10.1038/sj.bjc.6600540 ↗
4. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer10.1023/A:1012259625746 ↗
5. Cisplatin in cancer therapy: Molecular mechanisms of action10.1016/j.ejphar.2014.07.025 ↗
6. Platinum-based anticancer agents: Innovative design strategies and biological perspectives10.1002/med.10038 ↗
7. Anticancer activity and tissue distribution of platinum (II) complex with lignin-derived polymer of benzene-poly-carboxylic acids10.1016/j.jtemb.2016.11.009 ↗
8. Novel water-soluble lignin derivative BP-Cx-1: Identification of components and screening of potential targets in silico and in vitro10.18632/oncotarget.24990 ↗
9. Exploring bioactivity potential of polyphenolic water-soluble lignin derivative10.1016/j.envres.2020.110049 ↗
10. Efficacy and tolerability of BP-C1 in metastatic breast cancer: A Phase II, randomized, double-blind, and placebo-controlled Thai multi-center study
11. Positive effects on hematological and biochemical imbalances in patients with metastatic breast cancer stage IV, of BP-C1, a new anticancer substance
12. Protein binding: What does it mean?10.1177/106002808902300706 ↗
13. Speciation of oxaliplatin adducts with DNA nucleotides10.1039/c1mt00041a ↗
14. The binding assessment with human serum albumin of novel six-coordinate Pt(IV) complexes, containing bidentate nitrogen donor/methyl ligands
15. Dabrowiak, J.C. (2017). Metals in Medicine, Wiley & Sons Ltd.10.1002/9781119191377 ↗
16. Accurate quantification of carboplatin adducts with serum proteins by monolithic chromatography coupled to ICPMS with isotope dilution analysis10.1039/C8JA00409A ↗
17. The next generation of platinum drugs: Targeted pt(ii) agents, nanoparticle delivery, and Pt(IV) prodrugs10.1021/acs.chemrev.5b00597 ↗
18. Platinum drugs binding to human serum albumin: Effect of non-steroidal anti-inflammatory drugs10.1016/j.jphotochem.2014.05.013 ↗
19. Park, C.R., Kim, H.Y., Song, M.G., Lee, Y.S., Youn, H., Chung, J.K., Cheon, G.J., and Kang, K.W. (2020). Efficacy and Safety of Human Serum Albumin-Cisplatin Complex in U87MG Xenograft Mouse Models. Int. J. Mol. Sci., 21.10.3390/ijms21217932 ↗
20. Nedaplatin: A cisplatin derivative in cancer chemotherapy10.2147/CMAR.S35785 ↗
21. Rapid determination of platinum plasma concentrations of chemotherapy patients using total reflection X-ray fluorescence10.1016/j.sab.2006.09.006 ↗
22. Platinum drugs and neurotoxicity: Effects on intracellular calcium homeostasis10.1007/s10565-013-9252-3 ↗
23. Kireeva, G., Kruglov, S., Maydin, M., Gubareva, E., Fedoros, E., Zubakina, E., Ivanenko, N., Bezruchko, M., and Solovyev, N. (2020). Modeling of Chemoperfusion vs. Intravenous Administration of Cisplatin in Wistar Rats: Adsorption and Tissue Distribution. Molecules, 25.10.3390/molecules25204733 ↗
24. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding10.1002/jps.21317 ↗
25. Pharmacokinetics and tissue distribution of novel platinum containing anticancer agent BP-C1 studied in rabbits using sector field inductively coupled plasma mass spectrometry10.1002/dta.1824 ↗
26. Sigma-Aldrich (2021, April 04). HPLC Analysis of Warfarin™ Anticoagulant on Ascentis® C18. Available online: https://www.sigmaaldrich.com/technical-documents/articles/analytical-applications/hplc/hplc-analysis-of-warfarin-anticoagulant-g002340.html.
27. Protein binding of warfarin
28. The importance of plasma protein binding in drug discovery10.1517/17460441.2.1.51 ↗
29. Dasgupta, A. (2012). Chapter 4—Clinical Utility of Free Drug Monitoring. Therapeutic Drug Monitoring, Academic Press.10.1016/B978-0-12-385467-4.00001-4 ↗
30. Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry10.1039/ja9900500619 ↗
31. Redox speciation of iron, manganese, and copper in cerebrospinal fluid by strong cation exchange chromatography—Sector field inductively coupled plasma mass spectrometry10.1016/j.aca.2017.03.040 ↗
32. Biomedical copper speciation in relation to Wilson’s disease using strong anion exchange chromatography coupled to triple quadrupole inductively coupled plasma mass spectrometry10.1016/j.aca.2019.11.033 ↗
33. Fast and reliable ICP-MS quantification of palladium and platinum-based drugs in animal pharmacokinetic and biodistribution studies10.1039/D0AY01328E ↗
34. Comparative hydrolysis and plasma protein binding of cis-platin and carboplatin in human plasma in vitro10.1039/C0MT00058B ↗
35. Clinical pharmacokinetics and administration of established platinum drugs10.2165/00003495-200059004-00003 ↗
36. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection10.1016/j.talanta.2013.05.016 ↗
37. Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma-mass spectrometory10.1002/bdd.2197 ↗
38. Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration10.1093/jat/32.2.140 ↗